This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
Vulvar cancer is the fourth most common gynecologic malignancy after cervical, endometrial and ovarian cancers, accounting for about 4% of all gynecologic cancers. Historically, vulvar cancer was regarded as a disease of elderly women, but its pathogenesis and epidemiology were redefined in the late 20th century when its association with HPV (human papillomavirus) was revealed.
The concept of Vulvar Intraepithelial Neoplasia (VIN) was first introduced in the 1960s, and in 1986 the International Society for the Study of Vulvovaginal Disease (ISSVD) systematically classified VIN. VIN has been recognized as a precancerous lesion of invasive vulvar cancer, and the 2004 ISSVD classification divided it into HPV-associated VIN (usual-type VIN, uVIN) and non-HPV-associated VIN (differentiated VIN, dVIN). Differentiated VIN is associated with lichen sclerosus and tends to progress to invasive cancer faster than usual-type VIN.
In the history of treatment, radical vulvectomy and bilateral inguinal lymph node dissection were standard until the mid-20th century, but they carried considerable morbidity and reduced quality of life. From the 1980s–1990s, conservative surgical approaches according to lesion extent and the introduction of sentinel lymph node biopsy moved practice toward minimizing the extent of surgery while achieving equivalent therapeutic efficacy. In addition, definitive concurrent chemoradiotherapy (Definitive CCRT) was established as a treatment that can replace surgery in advanced vulvar cancer.
In Korea, national-level epidemiologic research on vulvar cancer has been conducted, and a nationwide prevalence study (2014–2018) published in the Journal of Korean Medical Science in 2022 analyzed the epidemiologic characteristics and treatment status of vulvar cancer in Korea. An association between low socioeconomic status (SES) and vulvar cancer prevalence was confirmed.
The causes of vulvar cancer are broadly divided into HPV-related pathways and non-HPV-related pathways.
HPV type 16 is found in about 40–50% of vulvar squamous cell carcinomas, and HPV type 18 also contributes in some. HPV-related vulvar cancer generally occurs in younger women (40s–50s) and progresses through vulvar intraepithelial neoplasia (uVIN). Smoking is an important cofactor that increases persistent HPV infection and the risk of vulvar cancer. The risk of HPV-related vulvar cancer is also increased in immunosuppressed states such as HIV infection.
Lichen sclerosus is the most important precursor lesion of non-HPV-related vulvar cancer (differentiated VIN→invasive cancer). TP53 mutations accumulate during chronic inflammation and cell regeneration, progressing through differentiated VIN to invasive squamous cell carcinoma. Non-HPV-related vulvar cancer occurs mainly in elderly women (60s–80s) and tends to have a poorer prognosis than the HPV-related type. Lichen planus is also known as a risk factor for non-HPV-related vulvar cancer.
The molecular genetic features of vulvar cancer differ distinctly between HPV-associated and non-HPV-associated types.
The E6 protein of high-risk HPV directs the p53 protein to the proteasomal degradation pathway, suppressing apoptosis, and the E7 protein binds the Rb (retinoblastoma) protein and activates the E2F transcription factor, promoting the cell cycle. This loss of p53/Rb function causes genomic instability and leads to malignant transformation of vulvar epithelial cells. p16 immunohistochemical positivity (block positivity) is used as a surrogate biomarker for HPV-associated VIN and vulvar cancer.
In non-HPV-associated vulvar cancer, somatic TP53 mutations (about 60–70%) are the most common genetic abnormality. DNA damage from chronic inflammation and reactive oxygen species contributes to the accumulation of TP53 mutations. PIK3CA mutations (about 25%) and PTEN loss (about 10%) are also observed. CDKN2A (p16) loss may also be observed in non-HPV-associated vulvar cancer. PD-L1 expression is a potential target for immunotherapy (checkpoint inhibitors) in some vulvar cancers.
Vulvar cancer is a rare gynecologic malignancy worldwide, accounting for about 0.5–1% of all cancers in women. About 6,500 new cases are diagnosed annually in the United States. According to a nationwide prevalence study conducted in Korea (2014–2018 health insurance claims data), vulvar cancer prevalence showed an increasing trend in 2018, and an association between low socioeconomic status (SES) and higher prevalence was confirmed. This is consistent with the findings of a previous study in Japan.
About 80% of vulvar cancers are squamous cell carcinoma (SCC), of which about 40% are HPV-associated and about 60% non-HPV-associated. The remaining 20% consist of melanoma (about 5%), Bartholin gland adenocarcinoma, basal cell carcinoma, Paget's disease and others. Worldwide, the incidence of HPV-related vulvar cancer is decreasing with the spread of HPV vaccination, but the incidence of non-HPV-related (lichen sclerosus-associated) vulvar cancer is expected to rise with population aging. Vulvar cancer occurs mainly in women in their 60s–70s, but the HPV-related type also occurs in the 40s–50s.
The pathophysiology of vulvar cancer is understood as two independent pathways.
High-risk HPV (mainly types 16 and 18) infection → persistent infection and genomic integration of HPV DNA in vulvar epithelial cells → expression of E6/E7 proteins → p53 degradation (E6-mediated) and suppression of Rb function (E7-mediated) → cell cycle dysregulation and genomic instability → formation of usual-type vulvar intraepithelial neoplasia (uVIN) → progression to vulvar squamous cell carcinoma. This pathway progresses over years to decades, and smoking and immunosuppression accelerate progression.
Chronic inflammation of lichen sclerosus → accumulation of DNA damage from reactive oxygen species (ROS) → occurrence of TP53 mutation → formation of differentiated vulvar intraepithelial neoplasia (dVIN) → rapid progression to vulvar squamous cell carcinoma. Progression from differentiated VIN to invasive cancer is much faster than from usual-type VIN (months to years), and the prognosis is also poorer.
The symptoms of vulvar cancer are nonspecific early on, so diagnosis is often delayed.
No standard screening program for vulvar cancer has been established for the general population.
HPV vaccination is effective in preventing vulvar intraepithelial neoplasia (uVIN) and HPV-related vulvar cancer. In Korea, the quadrivalent HPV vaccine (Gardasil) is included in the national immunization program for 12-year-old adolescent girls. When completed before sexual debut, it is 70–90% effective in preventing vulvar intraepithelial neoplasia caused by HPV types 16/18.
Patients are taught how to perform vulvar self-examination using a mirror and are instructed to visit a medical facility immediately if new lesions, changes or symptoms occur.
Stage I: confined to the vulva or perineum; stage IA: ≤2 cm, stromal invasion ≤1 mm; stage IB: >2 cm or stromal invasion >1 mm. Stage II: invasion of adjacent structures (lower 1/3 of the urethra, lower 1/3 of the vagina, anus). Stage III: inguinal lymph node metastasis. Stage IV: invasion of the upper 2/3 of the urethra, upper 2/3 of the vagina, bladder or rectum, or distant metastasis.
Wide local excision is the standard treatment for early vulvar cancer (FIGO stage IA/IB), aiming to secure negative margins (at least 8 mm). Inguinal lymph node evaluation is performed when stromal invasion is >1 mm, and sentinel lymph node biopsy (SLNB) minimizes unnecessary inguinal lymph node dissection. When the sentinel node is negative, complete lymph node dissection can be omitted. In advanced vulvar cancer, radical vulvectomy and bilateral inguinal lymph node dissection may be needed.
Adjuvant radiotherapy is given for positive margins, metastasis to 2 or more inguinal lymph nodes, or extracapsular extension. In advanced or unresectable vulvar cancer, cisplatin- or mitomycin C-based definitive concurrent chemoradiotherapy (Definitive CCRT) is an alternative to surgery.
In metastatic or recurrent vulvar cancer, cisplatin-based chemotherapy, paclitaxel, gefitinib (an EGFR inhibitor) and others are considered. In PD-L1-positive or MSI-H tumors, immune checkpoint inhibitors such as pembrolizumab may be considered.
| FIGO stage | 5-year survival |
|---|---|
| Stage I (localized, lymph node-negative) | >90% |
| Stage II (invasion of adjacent structures) | About 80% |
| Stage III (lymph node-positive) | About 40–60% (depending on the number of metastatic lymph nodes) |
| Stage IV (distant metastasis) | About 15–20% |
Adverse prognostic factors include lymph node metastasis (most important), tumor size, depth of stromal invasion, lymphovascular invasion, positive margins, and the non-HPV-related type (TP53-mutant type). HPV-positive vulvar cancer tends to have a better prognosis than HPV-negative vulvar cancer. Early detection is decisive for prognosis, and management of lichen sclerosus and regular checkups for early-stage diagnosis are important.